Picture of WuXi Biologics (Cayman) logo

2269 WuXi Biologics (Cayman) Cashflow Statement

0.000.00%
hk flag iconLast trade - 00:00
HealthcareHighly SpeculativeLarge CapHigh Flyer

Annual cashflow statement for WuXi Biologics (Cayman), fiscal year end - December 31st, CNY millions except per share, conversion factor applied.

2021
December 31st
2022
December 31st
2023
December 31st
2024
December 31st
2025
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:ARSARSARSARSARS
Standards:
IFRS
IFRS
IFRS
IFRS
IFRS
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line3,9935,3584,1744,8347,257
Depreciation
Amortisation
Non-Cash Items2709431,003839767
Unusual Items
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital-1,313-1,560-1,679-1,893-3,131
Change in Accounts Receivable
Change in Inventories
Change in Other Assets
Change in Accounts Payable
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities3,4315,5424,6685,2176,341
Capital Expenditures-6,523-5,868-4,221-3,930-3,685
Purchase of Fixed Assets
Other Investing Cash Flow Items-3,079-39.9992-12.1598
Acquisition of Business
Sale of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Change in Net Investments
Purchase of Investments
Change in Net Intangibles
Other Investing Cash Flow
Cash from Investing Activities-9,602-5,908-3,228-3,942-3,087
Financing Cash Flow Items-10450892.6-1,2943.5
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities8,209-2,5921,961-2,750-2,164
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash1,908-2,6083,275-1,391935